Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Escitalopram is an antidepressant inhibitor of the serotonin reuptake. On the market in
France since 2002.
Prevalence of emotional distress in patients with cancer is 30-50%. this prevalence may vary
regarding the tumor localisation, the population, intensity of the symptoms...
Incidence of ENT cancer is highly significant in France, it is one of the most important in
the world 37 out of 100 000. it is in patients with ENT cancer that the prevalence of
depression is the most important (22%-57%).
Researches appears necessary to assessed the efficacy of antidepressant treatments with as
primary objective not only the decrease of depressive symptoms but also an ensemble of physic
and psychological symptoms.